Cu(ATSM) Cuts Alzheimer’s Protein 42% in Mice as Brain Clearance Pumps Rise 24.1%
Updated
Updated · PsyPost · Jul 15
Cu(ATSM) Cuts Alzheimer’s Protein 42% in Mice as Brain Clearance Pumps Rise 24.1%
3 articles · Updated · PsyPost · Jul 15
Summary
A 56-day oral Cu(ATSM) regimen restored key blood-brain barrier P-glycoprotein pumps in APP/PS1 Alzheimer’s mice, linking the repair to lower amyloid-beta levels and better cognition.
The treated mice showed a 42% drop in toxic amyloid-beta and nearly 44% better spatial learning, while untreated Alzheimer’s mice had a 30.6% deficit in those clearance pumps versus healthy controls.
At 30 mg per kg daily, the drug raised copper in brain microvessels by nearly 230%; a radioactive tracer test also pointed to improved amyloid removal, though only as an 11.9% trend at 10 minutes.
Benefits were strongest in long-term spatial tasks such as the Barnes maze, where treated mice found the escape box faster and made fewer errors, but recognition-memory deficits were not reversed.
Researchers said the findings are still preclinical and do not prove the pumps alone drove the effect, though Cu(ATSM) has already entered clinical testing for Parkinson’s and ALS and is being eyed for Alzheimer’s trials.
A copper drug reboots the brain's 'cleanup crew'. Is this the key to reversing Alzheimer's damage?
Could boosting the brain's natural defense system unintentionally block other life-saving medicines from working?
Cu(ATSM) Shows 42% Amyloid-Beta Reduction and 44% Memory Improvement in Alzheimer’s Mouse Models: A New Hope for Neurodegenerative Disease
Overview
Recent preclinical research highlights Cu(ATSM) as a promising candidate for Alzheimer's disease, showing the ability to address key features like blood vessel dysfunction and memory loss. Cu(ATSM) works by restoring the function of the blood-brain barrier and may also enhance the activity of microglia, the brain’s immune cells. This dual action helps microglia more effectively break down toxic plaques that build up in the brain. These findings lay a strong foundation for exploring biometal therapies like Cu(ATSM), offering hope for new ways to combat Alzheimer’s disease.